Related Experiment Video

Updated: Mar 31, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib

Yiyi Yan1, Axel Grothey1

  • 1Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

Oncotargets and Therapy
|October 29, 2015
PubMed

Insights

Molecular profiling in metastatic colorectal cancer (mCRC) aids targeted therapies. This review focuses on RAS, BRAF, and MMR testing, especially for regorafenib treatment response in mCRC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastatic colorectal cancer (mCRC) is a complex disease with improving outcomes due to targeted therapies like anti-EGFR antibodies and VEGF inhibitors.
  • Biomarker identification, such as RAS mutation profiling, enhances patient selection for specific treatments and improves survival.

Purpose of the Study:

  • To review the clinical evidence for molecular profiling in mCRC.
  • To examine the role of RAS, BRAF, and MMR testing in targeted therapies.
  • To specifically focus on the molecular and genetic markers associated with regorafenib treatment response in mCRC.

Main Methods:

  • Literature review of clinical evidence.
  • Analysis of studies on molecular profiling in mCRC.
  • Examination of data related to targeted therapies, including regorafenib.

Main Results:

  • Targeted therapies have significantly improved mCRC treatment outcomes.
  • Predictive biomarkers like RAS mutations are crucial for selecting patients for anti-EGFR therapies.
  • The molecular markers for regorafenib response require further characterization.

Conclusions:

  • Molecular profiling, including RAS, BRAF, and MMR testing, is integral to modern mCRC management.
  • Further research is needed to identify biomarkers that predict response to multikinase inhibitors like regorafenib.
Keywords:
metastatic colon cancermolecular profilingregorafenibtargeted therapy

More Related Videos

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts10:33

Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts

Published on: April 29, 2014

11.6K
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

14.5K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K